Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Lacosamide as treatment of epileptic seizures - cost utility results for Sweden.

Bolin, Kristian LU ; Berggren, Fredrik LU and Forsgren, L (2010) In Acta Neurologica Scandinavica 121. p.406-412
Abstract
Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost utility results for Sweden. Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2009.01320.x. (c) 2010 The Authors Journal compilation (c) 2010 Blackwell Munksgaard. Objectives - To calculate cost per additional quality-adjusted life-year (QALY) for lacosamide as adjunctive treatment for patients with uncontrolled partial-onset seizures as compared to no adjunctive treatment. Materials and methods - A decision-tree simulation model was constructed to calculate the number of seizures and health-care utilization for treated and untreated with lacosamide, respectively. Prices from 2007 were used for all costs. Results - All results were calculated for a 24-, 18-,... (More)
Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost utility results for Sweden. Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2009.01320.x. (c) 2010 The Authors Journal compilation (c) 2010 Blackwell Munksgaard. Objectives - To calculate cost per additional quality-adjusted life-year (QALY) for lacosamide as adjunctive treatment for patients with uncontrolled partial-onset seizures as compared to no adjunctive treatment. Materials and methods - A decision-tree simulation model was constructed to calculate the number of seizures and health-care utilization for treated and untreated with lacosamide, respectively. Prices from 2007 were used for all costs. Results - All results were calculated for a 24-, 18-, 12- and 6-months follow-up. The cost per additional QALY was estimated to euro 27,641 (24 months). Using a willingness-to-pay threshold for a QALY of euro 50,000 the net marginal value of using lacosamide was estimated to about euro 850,000 per 1000 patients. Conclusions - The estimated cost per QALY gained falls within the range of reported estimates of the willingness-to-pay for an additional QALY. The results imply that lacosamide is cost-effective in the treatment of uncontrolled partial-onset seizures (1 euro approximately 9.6 SEK). (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Neurologica Scandinavica
volume
121
pages
406 - 412
publisher
Wiley-Blackwell
external identifiers
  • wos:000277783900007
  • pmid:20199516
  • scopus:77952665352
ISSN
1600-0404
DOI
10.1111/j.1600-0404.2010.01342.x
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: The Vårdal Institute (016540000), Division of Health Economics and Forensic Medicine (Closed 2012) (013040050)
id
284f9ab2-6c01-4f5b-b496-d3b222b5f1c9 (old id 1582591)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20199516?dopt=Abstract
date added to LUP
2016-04-04 09:26:42
date last changed
2022-01-29 17:54:41
@article{284f9ab2-6c01-4f5b-b496-d3b222b5f1c9,
  abstract     = {{Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost utility results for Sweden. Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2009.01320.x. (c) 2010 The Authors Journal compilation (c) 2010 Blackwell Munksgaard. Objectives - To calculate cost per additional quality-adjusted life-year (QALY) for lacosamide as adjunctive treatment for patients with uncontrolled partial-onset seizures as compared to no adjunctive treatment. Materials and methods - A decision-tree simulation model was constructed to calculate the number of seizures and health-care utilization for treated and untreated with lacosamide, respectively. Prices from 2007 were used for all costs. Results - All results were calculated for a 24-, 18-, 12- and 6-months follow-up. The cost per additional QALY was estimated to euro 27,641 (24 months). Using a willingness-to-pay threshold for a QALY of euro 50,000 the net marginal value of using lacosamide was estimated to about euro 850,000 per 1000 patients. Conclusions - The estimated cost per QALY gained falls within the range of reported estimates of the willingness-to-pay for an additional QALY. The results imply that lacosamide is cost-effective in the treatment of uncontrolled partial-onset seizures (1 euro approximately 9.6 SEK).}},
  author       = {{Bolin, Kristian and Berggren, Fredrik and Forsgren, L}},
  issn         = {{1600-0404}},
  language     = {{eng}},
  pages        = {{406--412}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Acta Neurologica Scandinavica}},
  title        = {{Lacosamide as treatment of epileptic seizures - cost utility results for Sweden.}},
  url          = {{http://dx.doi.org/10.1111/j.1600-0404.2010.01342.x}},
  doi          = {{10.1111/j.1600-0404.2010.01342.x}},
  volume       = {{121}},
  year         = {{2010}},
}